Search This Blog

Thursday, September 3, 2026

Climb Bio reports positive Phase 1 CLYM116 data in IgA nephropathy supporting every-12-week dosing

 

Climb Bio reports positive Phase 1 CLYM116 data in IgA nephropathy supporting every-12-week dosing

  • CLYM116 showed prolonged half-life with deep APRIL and IgA suppression in initial Phase 1 study data.
  • Phase 2 trial of CLYM116 in IgA nephropathy is ongoing following the positive initial Phase 1 results.
  • Climb Bio targets a Phase 3 start for CLYM116 in IgA nephropathy in 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)